Table 2.
Severity and outcomes of COVID-19 based on neurological pathophysiology confirmed through MRI findings for patients (n = 171).
| Pathophysiology | N | Severe n (%) |
Non-Severe n (%) |
p-Value | Fatal n (%) |
Non-Fatal n (%) |
p-Value |
|---|---|---|---|---|---|---|---|
| Ischemic stroke Non-ischemic stroke |
62 109 |
35(36) 61(64) |
27(36) 48(64) |
0.951 | 25(51) 24(49) |
37(30) 85(70) |
0.011 * |
| Hemorrhagic stroke Non-hemorrhagic stroke |
41 130 |
30(31) 66(69) |
11(15) 64(85) |
0.012 * | 17(35) 32(65) |
24(20) 98(80) |
0.037 * |
| Encephalitis Non-encephalitis |
24 147 |
17(18) 79(82) |
7(9) 68(91) |
0.118 | 3(6) 46(94) |
21(17) 101(83) |
0.059 |
| CNS inflammatory Non-inflammatory |
44 127 |
24(25) 72(75) |
20(27) 55(73) |
0.805 | 11(22) 38(78) |
33(27) 89(73) |
0.534 |
| Encephalopathy Non-encephalopathy |
11 160 |
11(11) 85(89) |
0(0) 75(100) |
0.002 * | 6(12) 43(88) |
5(4) 117(96) |
0.049 * |
| GBS and its variant Non-GBS |
3 168 |
1(1) 95(99) |
2(3) 73(97) |
0.422 | 0(0) 49(100) |
3(2) 119(98) |
0.268 |
| Olfactory bulb enhancement No olfactory bulb enhancement |
3 168 |
0(0) 96(100) |
3(4) 72(96) |
0.048 * | 0(0) 49(100) |
3(2) 119(98) |
0.268 |
| Other cranial nerve enhancement Non-cranial nerve enhancement |
6 165 |
0(0) 96(100) |
6(8) 69(92) |
0.005 * | 0(0) 49(100) |
6(5) 116(95) |
0.114 |
| Others (Yes) Others (No) |
6 165 |
4(4) 92(96) |
2(3) 73(97) |
0.597 | 3(6) 46(94) |
3(2) 119(98) |
0.239 |
* p-value significant (bold) at <0.05.